OR WAIT null SECS
April 04, 2024
Lonza has made a deal with Acumen Pharmaceuticals to manufacture sabirnetug, a mAb that will soon be entering Phase II development for treating Alzheimer’s disease.
March 15, 2024
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection
March 02, 2024
The authors evaluated the potential of direct filtration for multiple biopharmaceutical candidates. This article is Part 2 of the study.
February 12, 2024
Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.
February 07, 2024
Purolite and Repligen have commercially launched a new CH1 affinity resin for the purification of specialized mAbs.
February 02, 2024
The authors present a methodology to assess the contribution of individual filters to overall capacity of the direct filtration train, and elucidate how capacity is affected by characteristics of the cell culture broth and process parameters, including for enhanced upstream processes such as those incorporating high cell density perfusion.
January 22, 2024
Abzena has launched its AbZelect platforms, designed for improving cell line development.
January 02, 2024
Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.
November 16, 2023
Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency.
November 02, 2023
As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.